OpenAI Explores New Revenue Streams in Pharma: Plans "Investment Plus Royalty" Model to Target AI-Driven Biotech Innovation

Stock News02-04

According to information obtained by Zhitong Finance APP, OpenAI CEO Sam Altman indicated that the company is considering investing in or subsidizing firms that heavily utilize its artificial intelligence technology for discovering new drugs or therapies, and may charge corresponding patent royalties. Speaking at the Cisco Systems AI conference on Tuesday, Altman stated that AI developers could opt to partner with pharmaceutical companies to share the costs of using their AI models, and subsequently "receive some royalties" from the discoveries made by those companies. He mentioned that the developer of ChatGPT currently has no such partnerships in place. "We are not doing that right now, but I think the frontier of scientific discovery with AI will require so much capital that in some cases, we might view ourselves as an investor," he said. OpenAI and its competitors, such as Alphabet (GOOGL.US)-owned Google and Anthropic, are increasingly focusing on AI applications in science and healthcare—ranging from using the technology to help guide new drug research to reviewing personal medical data. Altman's comments provide the market with clearer insight into how the company views monetizing its technological breakthroughs. Last month at the World Economic Forum in Davos, OpenAI Chief Financial Officer Sarah Friar had stated that the company would take a share of the proceeds from discoveries achieved using its AI software. However, Altman clarified that OpenAI will not charge customers who merely use its models via an application programming interface (API).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1181461711?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 10:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181461711","market":"sh","top_or_hot":-1,"title":"OpenAI Explores New Revenue Streams in Pharma: Plans \"Investment Plus Royalty\" Model to Target AI-Driven Biotech Innovation","media":"Stock News","content":"<p>According to information obtained by Zhitong Finance APP, OpenAI CEO Sam Altman indicated that the company is considering investing in or subsidizing firms that heavily utilize its artificial intelligence technology for discovering new drugs or therapies, and may charge corresponding patent royalties. Speaking at the Cisco Systems AI conference on Tuesday, Altman stated that AI developers could opt to partner with pharmaceutical companies to share the costs of using their AI models, and subsequently \"receive some royalties\" from the discoveries made by those companies. He mentioned that the developer of ChatGPT currently has no such partnerships in place. \"We are not doing that right now, but I think the frontier of scientific discovery with AI will require so much capital that in some cases, we might view ourselves as an investor,\" he said. OpenAI and its competitors, such as Alphabet (GOOGL.US)-owned Google and Anthropic, are increasingly focusing on AI applications in science and healthcare—ranging from using the technology to help guide new drug research to reviewing personal medical data. Altman's comments provide the market with clearer insight into how the company views monetizing its technological breakthroughs. Last month at the World Economic Forum in Davos, OpenAI Chief Financial Officer Sarah Friar had stated that the company would take a share of the proceeds from discoveries achieved using its AI software. However, Altman clarified that OpenAI will not charge customers who merely use its models via an application programming interface (API).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OpenAI Explores New Revenue Streams in Pharma: Plans \"Investment Plus Royalty\" Model to Target AI-Driven Biotech Innovation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOpenAI Explores New Revenue Streams in Pharma: Plans \"Investment Plus Royalty\" Model to Target AI-Driven Biotech Innovation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-04 10:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to information obtained by Zhitong Finance APP, OpenAI CEO Sam Altman indicated that the company is considering investing in or subsidizing firms that heavily utilize its artificial intelligence technology for discovering new drugs or therapies, and may charge corresponding patent royalties. Speaking at the Cisco Systems AI conference on Tuesday, Altman stated that AI developers could opt to partner with pharmaceutical companies to share the costs of using their AI models, and subsequently \"receive some royalties\" from the discoveries made by those companies. He mentioned that the developer of ChatGPT currently has no such partnerships in place. \"We are not doing that right now, but I think the frontier of scientific discovery with AI will require so much capital that in some cases, we might view ourselves as an investor,\" he said. OpenAI and its competitors, such as Alphabet (GOOGL.US)-owned Google and Anthropic, are increasingly focusing on AI applications in science and healthcare—ranging from using the technology to help guide new drug research to reviewing personal medical data. Altman's comments provide the market with clearer insight into how the company views monetizing its technological breakthroughs. Last month at the World Economic Forum in Davos, OpenAI Chief Financial Officer Sarah Friar had stated that the company would take a share of the proceeds from discoveries achieved using its AI software. However, Altman clarified that OpenAI will not charge customers who merely use its models via an application programming interface (API).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159938","symbol_name":"医药","start_time":0,"source_url":"","article_id":"1181461711","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181461711","pubTimestamp":1770172801,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to information obtained by Zhitong Finance APP, OpenAI CEO Sam Altman indicated that the company is considering investing in or subsidizing firms that heavily utilize its artificial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","09939":"开拓药业-B","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"OpenAI探索制药行业新收入来源：计划“投资加版税”模式瞄准人工智能驱动的生物技术创新","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"09939":1},"content_text":"According to information obtained by Zhitong Finance APP, OpenAI CEO Sam Altman indicated that the company is considering investing in or subsidizing firms that heavily utilize its artificial intelligence technology for discovering new drugs or therapies, and may charge corresponding patent royalties. Speaking at the Cisco Systems AI conference on Tuesday, Altman stated that AI developers could opt to partner with pharmaceutical companies to share the costs of using their AI models, and subsequently \"receive some royalties\" from the discoveries made by those companies. He mentioned that the developer of ChatGPT currently has no such partnerships in place. \"We are not doing that right now, but I think the frontier of scientific discovery with AI will require so much capital that in some cases, we might view ourselves as an investor,\" he said. OpenAI and its competitors, such as Alphabet (GOOGL.US)-owned Google and Anthropic, are increasingly focusing on AI applications in science and healthcare—ranging from using the technology to help guide new drug research to reviewing personal medical data. Altman's comments provide the market with clearer insight into how the company views monetizing its technological breakthroughs. Last month at the World Economic Forum in Davos, OpenAI Chief Financial Officer Sarah Friar had stated that the company would take a share of the proceeds from discoveries achieved using its AI software. However, Altman clarified that OpenAI will not charge customers who merely use its models via an application programming interface (API).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181461711","isCrawlerRequest":true}